Clinical Trial Update: Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing etanercept 50 mg once weekly to 25 mg twice weekly in ankylosing spondylitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• ENBREL (etanercept)
• Etanercept (etanercept)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED